Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy

Recombinant hybrid Q2 is able to induce T-cell proliferation, thus evidencing a potential therapeutic effect. Its reduced IgE-binding capacity envisages an excellent safety profile.